This is a study in healthy male volunteers to assess how a new test medicine is taken up and broken down by the body as well as its safety and tolerability.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Enrollment
5
On Day 1, participants will receive a single oral dose of GLPG3667
On Day 1, participants will receive a single microtracer microdose of \[14C\]-GLPG3667 as an intravenous infusion
On Day 1, participants will receive a single oral dose of \[14C\]-GLPG3667
Quotient Sciences Limited
Nottingham, United Kingdom
Recovery of total radioactivity (TRA) excreted in urine expressed as a percentage of the administered dose (Ae%)
Time frame: From Day 1 until at least Day 8 in Period 2
Recovery of TRA excreted in feces expressed as a percentage of the administered dose (Af%)
Time frame: From Day 1 until at least Day 8 in Period 2
Recovery of TRA excreted in urine and feces expressed as a percentage of the administered dose (At%)
Time frame: From Day 1 until at least Day 8 in Period 2
Percentage of TRA in plasma and excreta for metabolites of interest
Time frame: From Day 1 until at least Day 8 in Period 2
Absolute oral bioavailability (F[percentage]) of GLPG3667
Time frame: From Day 1 until Day 4 in Period 1
Frequency and severity of treatment-emergent adverse events (TEAEs), treatment-emergent serious adverse events (SAEs), and TEAEs leading to treatment discontinuations.
Time frame: From Day 1 through study completion, an average of 2 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.